A Diagnosis of “Possible” Mitochondrial Disease: An Existential Crisis

Sumit Parikh*, MD, Mitochondrial Medicine Center, Neurologic Institute, Cleveland Clinic, Cleveland, OH

Amel Karaa*, MD, Mitochondrial Disease Program, Genetics Unit, Massachusetts General Hospital, Boston, MA.

Amy Goldstein, MD, Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

Enrico Bertini, Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesu’ Children’s Research Hospital, Rome, Italy

Patrick F. Chinnery, MRC Mitochondrial Biology Unit & Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK

John Christodoulou, Neurodevelopmental Genomics Research Group, Murdoch Children’s Research Institute, Melbourne and Department of Paediatrics, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia

Bruce H. Cohen, Department of Pediatrics and Rebecca D. Considine Research Institute, Akron Children’s Hospital, Akron, OH, USA and Northeast Ohio Medical University, Rootstown, OH, USA

Ryan L. Davis, University of Sydney, Faculty of Medicine and Health, Northern Clinical School, Sydney, New South Wales, Australia; Department of Neurogenetics, Kolling Institute, University of Sydney and Royal North Shore Hospital, Sydney, New South Wales, Australia
Marni J. Falk, Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

Carl Fratter, NHS Specialized Services for Rare Mitochondrial Disorders of Adults and Children UK, Oxford, UK and Oxford Medical Genetics Laboratories, Oxford University Hospitals, Oxford, UK

Rita Horvath, Wellcome Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ UK; Department of Clinical Neurosciences at the University of Cambridge Box 165, Addenbrooke’s Hospital, Cambridge Biomedical Campus, Cambridge CB2 0QO

Mary Kay Koenig, Department of Pediatrics, Mitochondrial Center, University of Texas McGovern Medical School, Houston, Texas, USA

Michelangelo Mancuso, Department of Experimental and Clinical Medicine, Neurological Institute, University of Pisa, Italy

Shana McCormack, Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

Elizabeth M. McCormick, Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
Robert McFarland, Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, NE 2 4HH UK

Victoria Nesbitt, NHS Highly Specialised Services for Rare Mitochondrial Disorders, Oxford University Hospitals, Oxford, OX3 9DU, UK; Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK

Manuel Schiff, Reference Center for Inborn Errors of Metabolism, Robert-Debré University Hospital, APHP, UMR1141, PROTECT, INSERM, Université Paris-Diderot, Sorbonne Paris Cité, Paris, France

Hannah Steele, Department of Neurology, Sunderland Royal Hospital, Sunderland, SR4 7TP, UK. Previously at Wellcome Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ UK

Sylvia Stockler, Department of Pediatrics, Division of Biochemical Diseases, University of British Columbia

Carolyn Sue, University of Sydney, Faculty of Medicine and Health, Northern Clinical School, Sydney, New South Wales, Australia; Department of Neurogenetics, Kolling Institute, University of Sydney and Royal North Shore Hospital, Sydney, New South Wales, Australia; Department of Neurology, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, New South Wales, Australia

Mark Tarnopolsky, Department of Pediatrics, Neuromuscular and Neurometabolic Clinic, McMaster University, Hamilton, Canada

David Thorburn, Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, Victoria, Australia; Victorian Clinical Genetics Services, Royal Children’s Hospital, Melbourne,
Victoria, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia

Jerry Vockley, Department of Pediatrics, University of Pittsburgh School of Medicine; Center for Rare Disease Therapy, Children’s Hospital of Pittsburgh, Pittsburgh, PA 15224

Shamima Rahman, Mitochondrial Research Group, UCL Great Ormond Street Institute of Child Health, London, UK; Metabolic Unit, Great Ormond Street Hospital NHS Foundation Trust, London, UK

*These authors contributed equally to this manuscript.
Abstract
Primary genetic mitochondrial diseases are often difficult to diagnose, and the term “possible” mitochondrial disease is used frequently by clinicians when such a diagnosis is suspected. There are now many known phenocopies of mitochondrial disease. Advances in genomic testing have shown that some patients with a clinical phenotype and biochemical abnormalities suggesting mitochondrial disease may have other genetic disorders. In instances when a genetic diagnosis cannot be confirmed, a diagnosis of “possible” mitochondrial disease may result in harm to patients and their families, creating anxiety, delaying appropriate diagnosis and leading to inappropriate management or care. A categorization of “diagnosis uncertain”, together with a specific description of the metabolic or genetic abnormalities identified, is preferred when a mitochondrial disease cannot be genetically confirmed.

Author contributions

SP, AK, AG conceived the presented idea and prepared a document outline including needed supplementary material.
SP, AK, AG, SR developed and supervised the manuscript.
SP, AK, AG, EB, PFC, JC, BHC, RLD, MJF, CF, RH, MKK, MM, SM, EMM, RM, VN, MS, HS, SS, CS, MT, DT, JV, SR commented on, approved and helped expand on the presented idea, drafted and revised portions of the manuscript including supplementary materials and commented on and approved the final draft.

Details of funding: This project did not receive direct funding.

Patient consent and IRB: IRB involvement was not required for this project

Key Words:
Mitochondrial Disease Diagnosis, Genetic Disorders, Patient Harm
Introduction

Primary mitochondrial disorders (PMD) are genetic metabolic disorders that directly impair normal mitochondrial structure or function including electron-transport chain (ETC) activity.[1] They are due to mutations in either maternally-inherited mitochondrial DNA (mtDNA) or one of hundreds of nuclear DNA (nDNA) genes that encode components involved in mitochondrial structure and function. PMDs can present at any age and be multisystemic or selectively involve only a single organ. They can present as a well-defined canonical syndrome or a constellation of phenotypes, although typically at least one “red-flag” symptom is usually present at disease onset.[2]

With advances in next-generation sequencing (NGS) and the discovery of a multitude of new disease genes, the ability to diagnose PMDs has improved enormously compared to just a few years ago. The diagnosis still remains challenging due to heterogeneous manifestations combined with limitations of currently available biochemical and genetic testing methods. Despite recent advances, many individuals with suspected mitochondrial disease may remain without a confirmed genetic diagnosis, presenting a challenge to the clinician in not only establishing a mitochondrial disease diagnosis but also in knowing how to categorize, counsel and manage the patient with a suspected PMD where a genetic diagnosis is not yet possible. [3–7]

These limitations contribute to continued variation in diagnostic categorization of patients depending on the opinion of the treating provider.[8] Diagnostic terms such as “unlikely,” “possible” or “probable” mitochondrial disease, originally proposed as part of research diagnostic criteria[9–11] were developed prior to genetic advances and may end up being inaccurate and misleading to patients and care providers, impacting or limiting proper counseling and the pursuit of further diagnostic testing. The complex and variable clinical presentation of mitochondrial diseases means that many unexplained disorders could conceivably have a mitochondrial etiology, so if a concrete alternative diagnosis cannot be
made using conventional investigations, there is a tendency to use the label ‘possible’ mitochondrial as a working diagnosis until an alternative emerges. Patients and families may inadvertently be burdened by the fear of the progressive nature of PMDs, the potential complications and early demise, as PMDs have no known cure. Thus, a diagnosis of “possible” mitochondrial disease may do more harm than good and consequently a new categorization for these patients is necessary.

**Mitochondrial Disease can no longer be diagnosed on the basis of phenotypic features alone**

A high index of suspicion for the possibility of a mitochondrial disease is appropriate when there is multi-system involvement or the presence of so-called “red-flags” such as stroke-like episodes in a non-vascular distribution (seen in Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke [MELAS] syndrome), bilateral symmetrical T2-weighted hyperintense MRI lesions in the basal ganglia and/or brainstem (Leigh syndrome), or chronic progressive external ophthalmoplegia (CPEO) and myopathy. Some of these “red-flag” symptoms were the subject of a previous review.[2] However, the growing list of genetically confirmed mitochondrial diseases has also led to an expanding list of variable phenotypes that should be suspected in the differential diagnosis of PMD, some of which are outlined in Table 1. [12–14]

**Table 1 Differential diagnosis of selected phenotypes commonly associated with mitochondrial disease**

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Mitochondrial cause</th>
<th>Limited differential diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dystonia</td>
<td>Leigh syndrome, deafness-dystonia syndrome, other mitochondrial encephalomyopathies</td>
<td>Biotinidase deficiency, thiamine transporter deficiency 2, ADAR mutations (Aicardi- Goutières syndrome 6), organic acidaemias (especially glutaric aciduria type I), NBIA, acute (viral) necrotising encephalopathy, mutations in NUP62, RANBP2 and PDE8B, primary genetic dystonias</td>
</tr>
<tr>
<td>Epileptic encephalopathy</td>
<td>Alpers-Huttenlocher syndrome, many other</td>
<td>Many genetic epileptic encephalopathies, including Dravet syndrome and KCNQ2 mutations, Pyridoxine dependent</td>
</tr>
</tbody>
</table>

---

9
<table>
<thead>
<tr>
<th>Condition</th>
<th>Mitochondrial disorders</th>
<th>Epilepsies (Antiquitin deficiency, PNPO deficiency), viral encephalitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Progressive myoclonic epilepsy</td>
<td>MERRF</td>
<td>Ramsay Hunt syndrome, Unverricht-Lundborg disease, Lafora body disease, sialidosis, PRICKLE1 mutations</td>
</tr>
<tr>
<td>Leukoencephalopathy</td>
<td>Complex I deficiency, Complex II deficiency, SURF1 deficiency (rarely), disorders of mitochondrial translation and Fe-S cluster assembly</td>
<td>Vanishing white matter disease, lysosomal storage disorders, Canavan disease, Alexander disease, Pelizaeus-Merzbacher(-like), hypo/dysmyelination</td>
</tr>
<tr>
<td>Ataxia</td>
<td>ADCK3 mutations, ataxia-neuropathy syndromes e.g. SCAE, MIRAS, MERRF, NARP, disorders of mitochondrial translation and Q10 biosynthesis</td>
<td>Spinocerebellar ataxias, CAPOS syndrome</td>
</tr>
<tr>
<td>Demyelination</td>
<td>MNGIE</td>
<td>ADEM, multiple sclerosis</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>Mutations in POLG, MPV17, KARS and SURF1; part of multisystem disease in many mitochondrial disorders, e.g. MNGIE</td>
<td>Other non-mitochondrial genetic causes of Charcot-Marie-Tooth syndromes, riboflavine transporter deficiency, toxic neuropathies, critical illness</td>
</tr>
<tr>
<td>Ptosis and ophthalmpoplegia</td>
<td>PEO, KSS, MNGIE, MELAS</td>
<td>Some congenital myopathies, pseudo upgaze impairment in OPMD, horizontal gaze palsy and scoliosis (ROBO3 mutation)</td>
</tr>
<tr>
<td>Optic neuropathy</td>
<td>LHON, ADOA, Leigh syndrome</td>
<td>Toxic optic neuropathy (e.g. methanol, cyanide, tobacco)</td>
</tr>
<tr>
<td>Hypertrophic cardiomyopathy with lactic acidosis</td>
<td>Complex I deficiency, TMEM70 mutations, Sengers syndrome (AGK deficiency), disorders of mitochondrial translation</td>
<td>Viral infection</td>
</tr>
<tr>
<td>Dilated cardiomyopathy with lactic acidosis</td>
<td>Barth syndrome, disorders of mitochondrial phospholipid remodelling, other</td>
<td>Viral infection</td>
</tr>
<tr>
<td>Condition</td>
<td>Related Conditions</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Exocrine pancreatic insufficiency</td>
<td>Pearson syndrome, Cystic fibrosis</td>
<td></td>
</tr>
<tr>
<td>Diabetes and deafness</td>
<td>MIDD, other mtDNA mutations, Type II diabetes mellitus with incidental nonsyndromic deafness</td>
<td></td>
</tr>
<tr>
<td>Sideroblastic anaemia</td>
<td>Pearson syndrome, MLASA, TRNT1 deficiency, <em>PUS1</em> or <em>YARS2</em> mutations, Blackfan-Diamond syndrome, Schwachman-Diamond syndrome, X-linked sideroblastic anaemia</td>
<td></td>
</tr>
<tr>
<td>B cell immune deficiency</td>
<td>TRNT1 deficiency, Primary immunodeficiency disorder</td>
<td></td>
</tr>
<tr>
<td>Liver failure</td>
<td>Mitochondrial DNA (mtDNA) depletion syndromes, NBAS, LARS and IARS deficiencies, viral infection, lysosomal storage disorders, other syndromic genetic conditions</td>
<td></td>
</tr>
<tr>
<td>Renal tubulopathy/failure</td>
<td>Pearson and Kearns-Sayre syndromes, <em>RMND1</em>-related disease, Gitelman syndrome, Fanconi Bickel (<em>SLC2A2</em> mutations) syndrome, other syndromic genetic conditions</td>
<td></td>
</tr>
<tr>
<td>Myopathy</td>
<td>Part of multisystem disease in many mitochondrial disorders especially mtDNA depletion syndromes, Congenital muscular dystrophies, myositis, many other disorders</td>
<td></td>
</tr>
<tr>
<td>Rhabdomyolysis</td>
<td>Mitochondrial myopathies (e.g. <em>MTCO1</em>, <em>MTCO2</em>, <em>MTCO3</em> and <em>MTCYB</em> mutations), <em>LPIN1</em> mutations, fatty acid oxidation defects (VLCAD, LCHAD), TANGO deficiency, glycolytic defects, toxic, post-exercise</td>
<td></td>
</tr>
<tr>
<td>Low copper</td>
<td>Cytochrome oxidase deficiency, Menkes, <em>SLC33A1</em> mutations</td>
<td></td>
</tr>
<tr>
<td>Complex multisystem disorders</td>
<td>Many mitochondrial disorders, particularly in childhood, Congenital disorders of glycosylation, peroxisomal disorders, lysosomal storage disorders, other syndromic genetic conditions</td>
<td></td>
</tr>
</tbody>
</table>

**Key:**
- ADEM acute disseminated encephalomyelitis
- ADOA autosomal dominant optic atrophy
- CAPOS cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorineural hearing loss
- Fe-S iron-sulphur
- KSS Kearns-Sayre syndrome
In contrast, genetic testing has revealed that non-mitochondrial disorders may present with symptoms suggestive of mitochondrial disease. Without confirmatory genetic evidence, an erroneous diagnosis of a PMD may be made. For example, myopathy with ophthalmoplegia may also be seen in some cases of congenital myopathies with mutations in \textit{MYH2}, \cite{15} \textit{MTM1} in male patients and female carriers,\cite{16} \textit{DNM2},\cite{17} and recessive \textit{RYR1} mutations,\cite{18–22} as well as in late-onset nemaline myopathy\cite{23} and in congenital myasthenia caused by mutations in \textit{CHAT} encoding the choline acetyltransferase.\cite{24} Similarly, patients with branched-chain organic acidurias can manifest with non-hemodynamic strokes,\cite{25} as can patients with congenital disorders of glycosylation.\cite{26} Bilateral striatal necrosis (with MRI lesions resembling those observed in Leigh syndrome) has been reported with genetic mutations in the nuclear pore proteins \textit{NUP62}\cite{27} and \textit{RANBP2}\cite{28} or in the cyclic nucleotide phosphodiesterase \textit{PDE8B}.\cite{29} Many of these disorders may also be associated with secondary mitochondrial dysfunction on biochemical testing as discussed later and illustrated in Table 2. Clinicians clearly need to exercise caution when considering mitochondrial disease, in order not to narrow the differential too quickly simply based on aspects of the clinical phenotype and astutely ensure that even “red flag” features of a PMD are placed in the correct context of the patient’s comorbid symptoms, family history and course of disease.

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Mitochondrial defect</th>
<th>Reference by PubMed ID number</th>
</tr>
</thead>
<tbody>
<tr>
<td>AOA1 (APTX mutations)</td>
<td>Coenzyme Q$_{10}$</td>
<td>15699391</td>
</tr>
<tr>
<td>Desminopathy</td>
<td>CS, mtDNA depletion (35%)</td>
<td>26097489</td>
</tr>
<tr>
<td>Syndrome/Related Disorders</td>
<td>Mitochondrial Deficit</td>
<td>Gene/Pathway</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Dravet syndrome (SCN1A mutations)</td>
<td>Variable OXPHOS deficiencies</td>
<td></td>
</tr>
<tr>
<td><strong>EXOSC3 and EXOSC8 related diseases</strong></td>
<td>Low Complex I and pyruvate dehydrogenase activities, low mtDNA copy number, increased expression of mitochondrial genes</td>
<td></td>
</tr>
<tr>
<td>GLUT1 deficiency</td>
<td>Complex I</td>
<td></td>
</tr>
<tr>
<td>GM3 synthase deficiency</td>
<td>Respiratory chain dysfunction in fibroblasts and liver</td>
<td></td>
</tr>
<tr>
<td>LCHADD</td>
<td>Complex III, COX</td>
<td></td>
</tr>
<tr>
<td>Limb immobolization</td>
<td>COX and CS</td>
<td></td>
</tr>
<tr>
<td>Lysosomal diseases: GM1-gangliosidosis, mucopolysaccharidosis IIIC, multiple sulfatase deficiency, Krabbe disease, Gaucher disease, Niemann Pick disease type C</td>
<td>Multiple OXPHOS deficiencies attributed to excessive production of mitochondrial reactive oxygen species and dysregulated calcium homeostasis with mitochondria-induced apoptosis and neurodegeneration</td>
<td></td>
</tr>
<tr>
<td>MADD (ETFDH, ETFA or ETFB mutations)</td>
<td>Complex I and II deficiencies; Riboflavin and Coenzyme Q\textsubscript{10} responsive</td>
<td></td>
</tr>
<tr>
<td>Molybdenum co-factor deficiency</td>
<td>COX</td>
<td></td>
</tr>
<tr>
<td>MTHFR mutations</td>
<td>Complex I deficiency</td>
<td></td>
</tr>
<tr>
<td>Multiple carboxylase deficiency</td>
<td>Complex III</td>
<td></td>
</tr>
<tr>
<td>NBIA (PKAN)</td>
<td>Complex III</td>
<td></td>
</tr>
<tr>
<td>Neonatal haemochromatosis</td>
<td>Complex III (liver)</td>
<td></td>
</tr>
<tr>
<td>Neuroferritinopathy (FTL1)</td>
<td>Complex I or multiple Complex deficiency</td>
<td></td>
</tr>
<tr>
<td>NPHS3 (PLCE1 deficiency)</td>
<td>COX</td>
<td></td>
</tr>
<tr>
<td>Neuronal Cereoid Lipofuscinosis (CLN2 and CLN3-related)</td>
<td>Partial deficiency in fatty acid oxidation enzymes and the storage of subunit c of mitochondrial ATP synthase in fibroblasts</td>
<td></td>
</tr>
<tr>
<td><strong>ORAI1 related disease</strong></td>
<td>Impaired lipid metabolism and fatty acid oxidation in skeletal muscle, heart and liver due to abnormal store-operated Ca\textsuperscript{2+} entry</td>
<td></td>
</tr>
<tr>
<td>Organic acidemias</td>
<td>Coenzyme Q\textsubscript{10}, multiple OXPHOS deficiencies and free radical induced oxidative damage</td>
<td></td>
</tr>
<tr>
<td>Ras/MAPK pathway mutations</td>
<td>Variable OXPHOS deficiencies</td>
<td></td>
</tr>
<tr>
<td>Rett syndrome (MECP2 mutations)</td>
<td>Variable OXPHOS deficiencies</td>
<td></td>
</tr>
<tr>
<td>SCAR10</td>
<td>Coenzyme Q\textsubscript{10}</td>
<td></td>
</tr>
<tr>
<td>Spinal muscular atrophy</td>
<td>Complexes I-IV, mtDNA depletion</td>
<td></td>
</tr>
<tr>
<td>STXBP1 mutation (de novo)</td>
<td>Complex I</td>
<td></td>
</tr>
<tr>
<td>Zellweger syndrome</td>
<td>Complexes II+III, COX</td>
<td></td>
</tr>
</tbody>
</table>
Biochemical diagnostic tests remain imperfect

Consensus criteria to help standardize the evaluation of patients with potential PMD, outlining a streamlined approach and reviewing the strengths and limitations of many of the current testing modalities were suggested in 2015 by the Mitochondrial Medicine Society (MMS), an international group of clinicians specializing in mitochondrial disease.[30] This exercise aimed to decrease the variability that exists in approaches used by clinicians to diagnose PMDs.[8]

When a mitochondrial disorder is suspected, biochemical screening in blood, urine and cerebrospinal fluid (CSF) remain the initial tests of choice quickly followed by next-generation sequencing (NGS) of mtDNA and nDNA from white blood cells, with additional genetic studies in muscle when needed, particularly in adult-onset cases. Whole exome sequencing (WES) is useful, and along with whole genome sequencing (WGS) is quickly becoming the first or second line genetic test in patients with suspected mitochondrial disease.[1, 5]

Histopathological, biochemical and genetic analysis of tissue including muscle remain important tools to further delineate the phenotype and ascertain the relevance of any genetic variants identified in blood, but should no longer be considered first or second line tests when suspicion of a PMD is high and appropriate genetic testing is available.[30] Select disorders, such as CPEO, may warrant the need for further diagnostic testing in muscle. Additional considerations regarding these tests have been reviewed previously[30] and are summarized below and in Table 3 and discussed in detail in the supplementary material (Supplement – Testing).

Table 3 Limitations of Testing

Current Limitations of Biochemical Testing
Imperfect sensitivity and specificity
Secondary mitochondrial dysfunction leading to abnormal results
Inter-lab variability of methods and reference ranges
Challenges with tissue processing

Current Limitations of Genetic Testing
Incomplete understanding of the role of the entire genome in mitochondrial function
Novel genes still being identified
Interpretation of nuclear and mtDNA variants of uncertain significance
Lack of understanding of tissue-specificity of mtDNA mutations
Unclear relevance of low heteroplasmia levels of pathogenic mtDNA mutations
mtDNA deletions and depletion may be observed in non-mitochondrial disease

Challenges with biochemical testing
Biochemical studies in blood and urine such as lactate, amino acids, organic acids, and including the recently identified biomarkers growth differentiation factor 15 (GDF15) and fibroblast growth factor 21 (FGF21), along with functional assays in various tissues such as ETC enzyme analysis, all have less than optimal sensitivity and specificity, especially when interpreted in isolation from the clinical context.[30–35]

Abnormalities on ETC enzyme analysis may occur for a multitude of reasons outside of PMD including secondary mitochondrial dysfunction from other causes such as other genetic diseases, limb immobilization,[36] and in liver failure from non-mitochondrial causes.[37, 38]
The list of other genetic disorders where some degree of secondary mitochondrial dysfunction in various tissues is seen seems ever-growing (Table 2) and includes spinal muscular atrophy (SMA),[39] X-linked adrenoleukodystrophy (ALD),[40] Phelan-McDermid syndrome, Down syndrome, Zellweger syndrome, the “rasopathies” (disorders caused by mutations in the Ras-MAPK pathway) and a variety of other conditions.[41–46] Causes of this secondary dysfunction have been discerned for very few of these disorders and the extent of mitochondrial dysfunction is variable and may not meet the diagnostic criteria threshold for ‘definite’ mitochondrial disease.[47] Therefore, evidence of biochemical dysfunction on functional testing alone, especially when mild or moderate, should not lead to a conclusive diagnosis of PMD.[42, 45, 48][49][47] When used with rigor, mitochondrial disease criteria may help the
clinician selectively better stratify truly high-risk patients.[50] However, mitochondrial disease diagnostic criteria were all developed at a time prior to the advent of NGS, when only limited genetic testing was available, and strongly emphasized the importance of abnormal biochemical findings in tissue.[10, 50, 51] This inevitably led to many patients being diagnosed with ‘possible’ mitochondrial disease.

Challenges with genetic testing

The advent of rapid, relatively low cost, NGS technologies has allowed for a genetic diagnosis to be made in many more patients with PMD. A growing number of nuclear genes has been associated with mitochondrial function (1500 to-date) [52, 53] although only around 350 or so have firmly been linked to causing human mitochondrial disease.[1, 54, 55] With more routine use of WES, new nuclear genes impacting mitochondrial function continue to be discovered. In some patients with a prior suspected but unconfirmed mitochondrial disease diagnosis, WES has also identified non-mitochondrial diseases.[56] In other cases, variant and milder phenotypes of PMD have been identified.[57] The ability to detect clearly pathogenic mutations in suspected PMD via genetic studies remains imperfect, with a reported diagnostic yield ranging from 25-75%.[3–7] The lack of understanding of the entire genome beyond the exome and increasing findings of variants of unknown significance (VUS) add to the diagnostic complexity.

MtDNA can now be accurately sequenced in its entirety for a relatively low cost and it is possible to detect levels of heteroplasmy of less than 5% in tissue, including blood. Genetic testing of mtDNA continues to be impacted by aspects of tissue specificity of mutations in mtDNA and varying degrees of heteroplasmy in easily attainable tissue. With newer testing methods able to detect low levels of heteroplasmy, common pathogenic mtDNA mutations (such as m.3243A>G) at low mutation load may mistakenly be attributed to cause a patient’s phenotype.[58] These issues and others are discussed in further detail in the supplementary material (Supplement – Testing) but lead to the clear concern that simply testing the mitochondrial genome in leukocytes is not always adequate, and that mtDNA testing including
quantification and deletion analysis in other tissues (skeletal muscle, liver, buccal, urine sediment) may be needed. Furthermore, even though many defects in mtDNA maintenance may be diagnosed by WES, there remains a significant number in which the causative genes remain unknown. Muscle or liver biopsy (depending on the phenotype), along with reliable assessment of mtDNA copy number compared to age specific control ranges and/or long PCR for multiple deletions, are needed to diagnose these patients.

Despite the current limitations of genetic testing, the need for genetic confirmation of a PMD diagnosis is becoming a necessity. The number of phenocopies identified together with the less than perfect specificity of biochemical studies raises the concern of a mistaken diagnosis and the potential of missing a separate treatable disease. Accurate genetic diagnosis of a PMD allows care providers and affected families to better understand the condition, for the provision of appropriate genetic counseling, and for the development of targeted therapies. For some PMDs where the natural history is better known, clinicians and families can more accurately predict the disease course and provide appropriate clinical management and preventative care.[59] The need for a genetic diagnosis in PMD is now essential for eligibility in clinical trials. Pre-implantation genetic diagnosis for nuclear and mtDNA disorders and mitochondrial donation techniques also requires a prior confirmed genetic diagnosis.

**Ending a “Possible” Diagnosis of Mitochondrial Disease**

Previously established diagnostic criteria,[9–11] developed prior to advances in genetic testing, relied heavily on biochemical functional tests. They were intended to serve as research categorization tools in the era of only a basic understanding of mtDNA as it relates to mitochondrial illness and prior to our knowledge of any but a handful of the hundreds of nuclear genes that are now known to cause mitochondrial disease. In addition, they were often not adhered to in the strictest fashion by clinicians. These diagnostic categorizations subsequently infiltrated the clinic and many more patients began to be labelled as having
“possible” mitochondrial disease. Others have received the diagnosis of “mitochondrial myopathy” because of abnormalities seen in muscle histology or microscopy alone, even though this finding may exist due to other genetic, metabolic or neurodegenerative diseases.

While genetic testing has improved, it is not currently possible to confirm the diagnosis at a genomic level in every case. Some patients may have a coincidentally identified pathogenic mtDNA mutation with low levels of heteroplasmy or a VUS in a nuclear gene bioinformatically predicted to impact mitochondrial function that may make a clinician consider a “possible” mitochondrial disease diagnosis.

Given that patients with symptoms suggestive of mitochondrial disease may or may not ultimately have a PMD, it is increasingly important to establish better diagnostic criteria, or at least a unified approach to categorizing these patients, to avoid significant variability in diagnostic labelling, genetic counseling and management. With the growing number of clinical, biochemical and genetic phenocopies of PMD being identified, it has become prudent that a definitive diagnosis of mitochondrial disease should only be provided when a confirmed pathogenic genetic defect has been identified. Utmost caution must be used when providing a diagnosis based on biochemical abnormalities in tissue alone and the strictest application of biochemical diagnostic criteria is needed. Patients with strong biochemical and clinical evidence for a PMD should be periodically re-evaluated as diagnostic testing advances.

There is a clear concern that a diagnosis of “possible” mitochondrial disease may result in harm. First and foremost, some patients who receive a diagnosis of a “possible” or “suspected” mitochondrial disease may not recognize the impermanence of such a diagnosis and remain carrying this label for many years without having their symptoms periodically reassessed and a more specific diagnosis investigated as knowledge and diagnostic tools improve. Over time, the categorization of “possible” is often dropped by some providers and non-mitochondrial specialists providing routine care for the patient. Some families may cling to the diagnosis even after having had a different genetic disease confirmed, as it is the diagnosis they have become
most familiar with over time. Testing for another disorder may be delayed from the clinician’s side if they are not aware of this diagnostic uncertainty. Other treatable disorders may not be diagnosed, or diagnosis may be delayed.

A diagnosis of “possible” mitochondrial disease may also create an unfounded fear of worsening morbidity and mortality. Certain families of patients given a diagnosis of “possible” mitochondrial disease often overlook the uncertainty of the diagnosis and become overly concerned that they or a family member may manifest all of the symptoms a patient with a PMD may develop, including neurodegeneration or early death, even in instances where their symptoms are relatively mild.

Lastly, patients with a diagnosis of “possible” mitochondrial disease may receive inappropriate care or be over-medicalized. Counseling of disease expectations and management may vary based on how patients are categorized.[60] Unnecessary medical interventions may be offered to some during times of catabolic stress. Some medications may not be used due to a concern of potential mitochondrial toxicity. New symptoms that a patient may manifest may inappropriately be explained away by the underlying diagnostic label rather than looking for other potentially treatable causes. These and other concerns are summarized in Table 4.

**Table 4 Potential Harms Arising from a Diagnosis of “Possible” Mitochondrial Disease**

- Ending diagnostic odyssey prematurely
- Missing potentially treatable disorders
- Psychological burden of mitochondrial disease diagnosis: parent/patient fear of progressive or degenerative disorder
- Inaccurate recurrence risk counseling
- Inappropriate preventative care
- Unnecessary medical interventions at times of catabolic stress
- Avoidance of needed medications owing to fear of mitochondrial toxicity
- Inappropriate reproductive decisions taken
Some of these very issues and challenges are outlined in example cases provided in the supplementary material (Supplement – Cases). In addition to the disorders outlined in Table 2, the supplementary cases illustrate instances where a patient may have symptoms suggesting the possibility of mitochondrial disease, often with biochemical abnormalities suggesting mitochondrial dysfunction, but the final diagnosis is not a PMD. Diagnosis is often delayed due to the mistaken diagnosis. Examples include a manganese transporter disorder with bilateral basal ganglia hyperintensities and elevated FGF21 levels (Case 1), oculopharyngeal muscular dystrophy with ragged red and cytochrome c oxidase (COX)-negative fibers (Case 2), Lesch-Nyhan syndrome with putaminal and thalamic abnormalities, lactic acidosis and reduced Complex I enzymatic activity in muscle (Case 3) and Niemann-Pick Type C with Complex I deficiency leading to a delay in being prescribed Miglustat (Case 4). In some of these instances, mitochondrial functional testing was notably abnormal, meeting biochemical diagnostic criteria for a mitochondrial disease. In contrast, select other cases (Cases 5-8) illustrate a delayed PMD diagnosis due to limitations of genetic testing in blood, findings of low levels of heteroplasmy or findings of a VUS. Case 5 illustrates an instance of a female with MELAS-like symptoms. Other cases (Cases 6-8) show the challenges in interpreting nuclear and mtDNA VUS.

Recommendations
In patients without a confirmed genetic diagnosis, there is a need for clinicians and the mitochondrial disease community to utilize diagnostic labels that clearly state that the diagnosis is uncertain even when mitochondrial dysfunction has been identified. A category of “genetic diagnosis uncertain; mitochondrial biochemical dysfunction or mitochondrial genetic variant of unknown significance identified” is preferable to a diagnosis of “possible” or “probable” or “suspected” mitochondrial disease. Other terminology that should be avoided is listed in Table 5. Depending on the clinical situation, patients may be further stratified into a “high risk” for a PMD to guide management.

Table 5 Terminology to avoid when a mitochondrial diagnosis is uncertain
“Possible,” “Probable” or “Suspected” Mitochondrial Disease
Mitochondrial Myopathy
Mitochondrial Cytopathy
Mitochondrial Metabolism Disorder
Defect of Mitochondrial Metabolism

Our proposal to utilize a diagnostic label of “genetic diagnosis uncertain” for all such cases would allow clinicians and patients to remain actively engaged in the diagnostic odyssey, review the prior data periodically and take advantage of technological advances in genetic testing and new disease descriptions. Conducting relevant screening of other systems and monitoring for other organ involvement would allow better definition of the phenotype and not overlook disease progression. The clarity of the diagnostic label may prevent inappropriate or unnecessary care and allay fears of a progressive or degenerative disease.

Further categorization of selected patients as possible “high risk” for a PMD would allow for closer monitoring for mitochondrial disease related systemic comorbidities or extra cautions during times they are at risk of metabolic decompensations. If the phenotype is especially suggestive of a PMD, it may be appropriate to manage such a patient as if they have a genetically confirmed PMD for the time being – especially if they have previously experienced metabolic decompensation during times of illness or medical stress. Unexpected, acute changes in clinical status warrant thorough medical evaluation including laboratory testing to investigate potential mitochondrial dysfunction. However, the “diagnosis uncertain” designation would prevent any misunderstanding among medical teams. If the phenotype is not as suggestive of a PMD, it may be prudent to avoid over-medicalization of the patient and simply continue more routine monitoring.

As diagnostic standards for mitochondrial disease continue to evolve, these patients should remain under the care of a clinician who can assist in providing up-to-date recommendations regarding further testing. The MMS has such recommendations available online at www.mitosoc.org.
Conclusion
Despite advances in diagnostic techniques and molecular genetics, a subset of patients with suspected mitochondrial disease remains without a confirmed genetic diagnosis. The path these patients take to receiving a diagnosis is arduous and, at times, circuitous. Newer NGS based genetic studies offer the ability to streamline the approach to diagnosis for some patients. Others remain with a constellation of symptoms, findings of mitochondrial dysfunction on functional testing, and no clear pathogenic genetic mutation. Patients diagnosed with a “possible” mitochondrial disease might be found to have a non-mitochondrial genetic disorder once new testing modalities are utilized. A mistaken diagnosis of mitochondrial disease may prematurely end their diagnostic journey, over-medicalize their care, and potentially limit access to appropriate treatments for the actual underlying condition. To alleviate this dilemma, such patients would be better served by clinicians avoiding the diagnostic term “possible” mitochondrial disease.
Acknowledgements

RH is a Wellcome Trust Investigator (109915/Z/15/Z), who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). PFC is a Wellcome Trust Senior Fellow in Clinical Science (101876/Z/13/Z) and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UP_1501/2), the Medical Research Council (UK) Centre for Translational Muscle Disease (G0601943), EU FP7 TIRCON, and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. SR is supported by a Great Ormond Street Hospital Children's Charity Research Leadership Award (V1260) and by research grant funding from the NIHR Great Ormond Street Hospital Biomedical Research Centre and the Lily Foundation.

EB, SR and MR are members of the European Reference Network for Rare Hereditary Metabolic Disorders (METABERN) - Project ID No 739543. MetabERN is partly co-funded by the European Union in the framework of the Third Health Programme “ERN-2016 - Framework Partnership Agreement 2017-2021.

MM is supported by research grants from Telethon and MITOCON Italian patients’ association (grants GSP09004 and GSP16001)

MT would like to thank Dan Wright and family for a kind donation for research in mitochondrial disease and to Kathy Corkins and Warren Lammert and family for a kind donation to establish the Corkins-Lammert Mitochondrial Disease Center at McMaster University.
REFERENCES


34 Davis RL, Liang C, Edema-Hildebrand F, Riley C, Needham M, Sue CM. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. *Neurology* Published Online First: 18 October 2013. doi:10.1212/01.wnl.0000436068.43384.ef


57 Camara Y, Carreno-Gago L, Martin MA, Melia MJ, Blazquez A, Delmrio A, Garrabou G,


### Table 1: Differential diagnosis of selected phenotypes commonly associated with mitochondrial disease

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Mitochondrial cause</th>
<th>Limited differential diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dystonia</td>
<td>Leigh syndrome, deafness-dystonia syndrome, other mitochondrial encephalomyopathies</td>
<td>Biotinidase deficiency, thiamine transporter deficiency 2, ADAR mutations (Aicardi-Goutières syndrome 6), organic acidaemias (especially glutaric aciduria type I), NBIA, acute (viral) necrotising encephalopathy, mutations in NUP62, RANBP2 and PDE8B, primary genetic dystonias</td>
</tr>
<tr>
<td>Epileptic encephalopathy</td>
<td>Alpers-Huttenlocher syndrome, many other mitochondrial disorders</td>
<td>Many genetic epileptic encephalopathies, including Dravet syndrome and KCNQ2 mutations, Pyridoxine dependent epilepsies (Antiquitin deficiency, PNPO deficiency), viral encephalitis</td>
</tr>
<tr>
<td>Progressive myoclonic epilepsy</td>
<td>MERRF</td>
<td>Ramsay Hunt syndrome, Unverricht-Lundborg disease, Lafora body disease, sialidosis, PRICKLE1 mutations</td>
</tr>
<tr>
<td>Leukoencephalopathy</td>
<td>Complex I deficiency, Complex II deficiency, SURF1 deficiency (rarely), disorders of mitochondrial translation and Fe-S cluster assembly</td>
<td>Vanishing white matter disease, lysosomal storage disorders, Canavan disease, Alexander disease, Pelizaeus-Merzbacher-like, hypo/dysmyelination</td>
</tr>
<tr>
<td>Ataxia</td>
<td>ADCK3 mutations, ataxia-neuropathy syndromes e.g. SCAE, MIRAS, MERRF, NARP, disorders of coenzyme Q10 biosynthesis</td>
<td>Spinocerebellar ataxias, CAPOS syndrome</td>
</tr>
<tr>
<td>Demyelination</td>
<td>MNGIE</td>
<td>ADEM, multiple sclerosis</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>Mutations in POLG, MPV17, KARS and SURF1; part of multisystem disease in many mitochondrial disorders, e.g. MNGIE</td>
<td>Other non-mitochondrial genetic causes of Charcot-Marie-Tooth syndromes, riboflavin transporter deficiency, toxic neuropathies, critical illness</td>
</tr>
<tr>
<td>Condition</td>
<td>Cause</td>
<td>Associated Conditions</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ptosis and ophthalmoplegia</td>
<td>PEO, KSS, MNGIE, MELAS</td>
<td>Some congenital myopathies, pseudo upgaze impairment in <em>OPMD</em>, horizontal gaze palsy and scoliosis (<em>ROBO3</em> mutation)</td>
</tr>
<tr>
<td>Optic neuropathy</td>
<td>LHON, ADOA, Leigh syndrome</td>
<td>Toxic optic neuropathy (e.g. methanol, cyanide, tobacco)</td>
</tr>
<tr>
<td>Hypertrophic cardiomyopathy with lactic acidosis</td>
<td>Complex I deficiency, <em>TMEM70</em> mutations, Sengers syndrome (AGK deficiency), disorders of mitochondrial translation</td>
<td>Viral infection</td>
</tr>
<tr>
<td>Dilated cardiomyopathy with lactic acidosis</td>
<td>Barth syndrome, disorders of mitochondrial phospholipid remodelling, other mitochondrial cardiomyopathies</td>
<td>Viral infection</td>
</tr>
<tr>
<td>Exocrine pancreatic insufficiency</td>
<td>Pearson syndrome</td>
<td>Cystic fibrosis</td>
</tr>
<tr>
<td>Diabetes and deafness</td>
<td>MIDD, other mtDNA mutations</td>
<td>Type II diabetes mellitus with incidental nonsyndromic deafness</td>
</tr>
<tr>
<td>Sideroblastic anaemia</td>
<td>Pearson syndrome, MLASA, TRNT1 deficiency, <em>PUS1</em> or <em>YARS2</em> mutations</td>
<td>Blackfan-Diamond syndrome, Schwachman-Diamond syndrome, X-linked sideroblastic anaemia</td>
</tr>
<tr>
<td>B cell immune deficiency</td>
<td>TRNT1 deficiency</td>
<td>Primary immunodeficiency disorder</td>
</tr>
<tr>
<td>Liver failure</td>
<td>Mitochondrial DNA (mtDNA) depletion syndromes,</td>
<td>NBAS, LARS and IARS deficiencies, viral infection, lysosomal storage disorders, other syndromic genetic conditions</td>
</tr>
<tr>
<td>Renal tubulopathy/failure</td>
<td>Pearson and Kearns-Sayre syndromes, <em>RMND1</em>-related disease</td>
<td>Gitelman syndrome, Fanconi Bickel (<em>SLC2A2</em> mutations) syndrome, other syndromic genetic conditions</td>
</tr>
<tr>
<td>Myopathy</td>
<td>Part of multisystem disease in many mitochondrial disorders especially mtDNA depletion syndromes</td>
<td>Congenital muscular dystrophies, myositis, many other disorders</td>
</tr>
<tr>
<td>Rhabdomyolysis</td>
<td>Mitochondrial myopathies (e.g. <em>MTCO1, MTCO2, MTCO3</em> and <em>MTCYB</em> mutations)</td>
<td><em>LPIN1</em> mutations, fatty acid oxidation defects (VLCAD, LCHAD), TANGO deficiency, glycolytic defects, toxic, post-exercise</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Low copper</td>
<td>Cytochrome oxidase deficiency</td>
<td>Menkes, <em>SLC33A1</em> mutations</td>
</tr>
<tr>
<td>Complex multisystem disorders</td>
<td>Many mitochondrial disorders, particularly in childhood</td>
<td>Congenital disorders of glycosylation, peroxisomal disorders, lysosomal storage disorders, other syndromic genetic conditions</td>
</tr>
</tbody>
</table>

**Key:**
- ADEM acute disseminated encephalomyelitis
- ADOA autosomal dominant optic atrophy
- CAPOS cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorineural hearing loss
- Fe-S iron-sulphur
- KSS Kearns-Sayre syndrome
- LHON Leber hereditary optic neuropathy
- MERRF myoclonic epilepsy with ragged red fibers
- MIDD maternally inherited diabetes and deafness
- MIRAS mitochondrial recessive ataxia syndrome
- MLASA myopathy, lactic acidosis, sideroblastic anemia
- MNGIE mitochondrial neurogastrointestinal encephalomyopathy
- NBIA neurodegeneration with brain iron accumulation
- PEO progressive external ophthalmoplegia
- SCAE spinocerebellar ataxia with epilepsy
Table 2 Mitochondrial Dysfunction Identified in Other Genetic Disorders

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Mitochondrial defect</th>
<th>Reference by PubMed ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>AOA1 (APTX mutations)</td>
<td>Coenzyme Q&lt;sub&gt;10&lt;/sub&gt;</td>
<td>15699391</td>
</tr>
<tr>
<td>Desminopathy</td>
<td>CS, mtDNA depletion (35%)</td>
<td>26097489</td>
</tr>
<tr>
<td>Dravet syndrome (SCN1A mutations)</td>
<td>Variable OXPHOS deficiencies</td>
<td>20392657; 21906962</td>
</tr>
<tr>
<td>EXOSC3 and EXOSC8 related diseases</td>
<td>Low Complex I and pyruvate dehydrogenase activities, low mtDNA copy number, increased expression of mitochondrial genes</td>
<td>28687512; 24989451</td>
</tr>
<tr>
<td>GLU1 deficiency</td>
<td>Complex I</td>
<td>22156785</td>
</tr>
<tr>
<td>GM3 synthase deficiency</td>
<td>Respiratory chain dysfunction in fibroblasts and liver</td>
<td>22990144</td>
</tr>
<tr>
<td>LCHADD</td>
<td>Complex III, COX</td>
<td>16417669</td>
</tr>
<tr>
<td>Limb immobilization</td>
<td>COX and CS</td>
<td>19654872</td>
</tr>
<tr>
<td>Lysosomal diseases: GM1-gangliosidosis, mucopolysaccharidosis IIIC, multiple sulfatase deficiency, Krabbe disease, Gaucher disease, Niemann Pick disease type C</td>
<td>Multiple OXPHOS deficiencies attributed to excessive production of mitochondrial reactive oxygen species and dysregulated calcium homeostasis with mitochondria-induced apoptosis and neurodegeneration</td>
<td>28132808</td>
</tr>
<tr>
<td>MADD (ETFDH, ETFA or ETFB mutations)</td>
<td>Complex I and II deficiencies; Riboflavin and Coenzyme Q&lt;sub&gt;10&lt;/sub&gt; responsive</td>
<td>17412732</td>
</tr>
<tr>
<td>Molybdenum co-factor deficiency</td>
<td>COX</td>
<td>16417669</td>
</tr>
<tr>
<td>MTHFR mutations</td>
<td>Complex I deficiency</td>
<td>21131308</td>
</tr>
<tr>
<td>Multiple carboxylase deficiency</td>
<td>Complex III</td>
<td>16417669</td>
</tr>
<tr>
<td>NBIA (PKAN)</td>
<td>Complex III</td>
<td>16417669</td>
</tr>
<tr>
<td>Neonatal haemochromatosis</td>
<td>Complex III (liver)</td>
<td>16417669</td>
</tr>
<tr>
<td>Neuroferritinopathy (FTL1)</td>
<td>Complex I or multiple Complex deficiency</td>
<td>17142829</td>
</tr>
<tr>
<td>NPHS3 (PLCE1 deficiency)</td>
<td>COX</td>
<td>21365190</td>
</tr>
<tr>
<td>Neuronal Ceroid Lipofuscinosis (CLN2 and CLN3-related)</td>
<td>Partial deficiency in fatty acid oxidation enzymes and the storage of subunit c of mitochondrial ATP synthase in fibroblasts</td>
<td>8971698</td>
</tr>
<tr>
<td>Orai1 related disease</td>
<td>Impaired lipid metabolism and fatty acid oxidation in skeletal muscle, heart and liver due to abnormal store-operated Ca&lt;sup&gt;2+&lt;/sup&gt; entry</td>
<td>28132808</td>
</tr>
<tr>
<td>Organic acidemias</td>
<td>Coenzyme Q&lt;sub&gt;10&lt;/sub&gt;, multiple OXPHOS deficiencies and free radical induced oxidative damage</td>
<td>21329767; 28753922; 28753922</td>
</tr>
<tr>
<td>Ras/MAPK pathway mutations</td>
<td>Variable OXPHOS deficiencies</td>
<td>26097489</td>
</tr>
<tr>
<td>Rett syndrome (MECP2 mutations)</td>
<td>Variable OXPHOS deficiencies</td>
<td>26741492</td>
</tr>
<tr>
<td>SCAR10</td>
<td>Coenzyme Q&lt;sub&gt;10&lt;/sub&gt;</td>
<td>25182700</td>
</tr>
<tr>
<td>Condition</td>
<td>Complexes/Enzymes</td>
<td>OMIM Numbers</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>------------------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Spinal muscular atrophy</td>
<td>Complexes I-IV, mtDNA depletion</td>
<td>12557011; 25844556</td>
</tr>
<tr>
<td>STXBPI mutation <em>(de novo)</em></td>
<td>Complex I</td>
<td>25418441</td>
</tr>
<tr>
<td>Zellweger syndrome</td>
<td>Complexes II+III, COX</td>
<td>25287621; 28753922</td>
</tr>
</tbody>
</table>

Key: AOA1 oculomotor aprasia type 1, COX cytochrome c oxidase, CS citrate synthase, GLUT1 glucose transporter 1, LCHADD long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, MADD multiple acyl-CoA dehydrogenase deficiency, MAPK mitogen activated protein kinases, mtDNA mitochondrial DNA, NBIA neuronal brain iron accumulation, NPHS3 nephrotic syndrome type 3, OXPHOS oxidative phosphorylation, PKAN pantothenate kinase, SCAR10 autosomal recessive spinocerebellar ataxia-10,
Table 3 Limitations of Testing

Current Limitations of Biochemical Testing
Imperfect sensitivity and specificity
Secondary mitochondrial dysfunction leading to abnormal results
Inter-lab variability of methods and reference ranges
Challenges with tissue processing

Current Limitations of Genetic Testing
Incomplete understanding of the role of the entire genome in mitochondrial function
Novel genes still being identified
Interpretation of nuclear and mtDNA variants of uncertain significance
Lack of understanding of tissue-specificity of mtDNA mutations
Unclear relevance of low heteroplasmy levels of pathogenic mtDNA mutations
mtDNA deletions and depletion may be observed in non-mitochondrial disease

Table 4 Potential Harms Arising from a Diagnosis of “Possible” Mitochondrial Disease

Ending diagnostic odyssey prematurely
Missing potentially treatable disorders
Psychological burden of mitochondrial disease diagnosis: parent/patient fear of progressive or degenerative disorder
Inaccurate recurrence risk counseling
Inappropriate preventative care
Unnecessary medical interventions at times of catabolic stress
Avoidance of needed medications owing to fear of mitochondrial toxicity
Inappropriate reproductive decisions taken

Table 5 Terminology to avoid when a mitochondrial diagnosis is uncertain
“Possible,” “Probable” or “Suspected” Mitochondrial Disease
Mitochondrial Myopathy
Mitochondrial Cytopathy
Mitochondrial Metabolism Disorder
Defect of Mitochondrial Metabolism
Supplementary Material

Biochemical Testing Concerns

Once a mitochondrial disease is suspected, most testing protocols begin with assessing lactic acid, plasma or CSF amino acids and urine organic acids. Elevations of plasma lactic acid and certain amino acids (such as alanine, glycine, proline or threonine) or urinary organic acids (such as malate, fumarate or 3-methylglutaconic acid) may indicate mitochondrial dysfunction. Concerns regarding their sensitivity and specificity have been discussed previously, and they remain imperfect biomarkers in assessing mitochondrial dysfunction. However they continue to be routinely obtained since they are relatively inexpensive and may be used to guide the need for further testing.[1] Some have reported that when collected properly and considered in the correct clinical context, elevations in lactate may selectively have specificity as high as 83-100%[2–4] although this is not always the case.[5] Nonetheless, permanent urinary excretion of 3-methylglutaconic acid, if associated with a suggestive clinical picture, is usually a good indicator of PMD.[6] FGF21 and GDF15 are cytokines more recently associated with mitochondrial dysfunction in cases of myopathy but also have less than optimal sensitivity and specificity, often being elevated in non-mitochondrial diseases including diabetes, hypothyroidism, overfeeding, sepsis and other genetic diseases.[2, 7–13]

While evaluation of suspected mitochondrial disease now often quickly moves to molecular genetic testing, functional studies of the mitochondrial electron transport chain (ETC) are still important in many situations. However, in many centers they are no longer the first line test when mitochondrial disease is suspected. Functional assays include ETC enzymology via spectrophotometry, measurement of the presence of selected protein components within complexes and super-complexes via western blots and blue-native gel electrophoresis, and oxygen consumption rates using various substrates and inhibitors.
False positive results may be seen due to challenges in tissue processing and test application including improper tissue collection or handling, the impact of local anesthetic on results,[14] and utilizing reference ranges intended for quadriceps muscle for muscle tissue collected from other sites. ETC assays may have little to no margin between patient and control ranges and can also differ between different laboratories and make inter-laboratory comparison of test results extremely challenging. Multiple global health factors impact results, including exercise or the lack thereof, effects of chronic illness, and age of the patient. Secondary and potentially reversible ETC functional defects have also been observed following limb immobilisation,[15] and in liver failure from non-mitochondrial causes.[16, 17] ETC deficiency has been seen in ischaemia/reperfusion injury, sepsis and trauma.[18–20]

Even once these factors are seemingly accounted for, functional studies may lead to misdiagnoses and mistaken labels of a “possible” mitochondrial disease, because other genetic conditions may sometimes be associated with a secondary mitochondrial dysfunction.[21] For instance, multiple ETC deficiencies and mtDNA depletion have been reported in Spinal Muscular Atrophy (SMA).[22] Downregulated muscle mitochondrial biogenesis has been shown to underlie this mitochondrial dysfunction in SMA.[23] Abnormal accumulation of very long-chain fatty acids in X-linked adrenoleukodystrophy (ALD) leads to a defect in mitochondrial respiration and biogenesis with chronic redox imbalance, which in turn is partly responsible for neurodegeneration.[24] Other examples exist for Phelan-McDermid syndrome, Down syndrome, Zellweger syndrome, the rasopathies and a variety of other conditions.[25–30] Mechanistic links for this secondary dysfunction have been described for very few of these disorders.[31] Thus, evidence of biochemical dysfunction on functional testing cannot provide a conclusive diagnosis of mitochondrial disease.

Functional mitochondrial studies do serve several key roles. As genetic testing remains imperfect, biochemical testing may help to better elucidate the degree of mitochondrial dysfunction and potentially define the pathogenicity of genetic variants of uncertain significance (VUS). Functional tests can also provide further evidence when genomic studies
identify a pathogenic mutation in a single allele for an autosomal recessive condition with a compatible clinical phenotype and there is a concern that a second pathogenic disease allele may not have been identified by exome sequencing.[32]

**Genetic Testing Concerns**

The advent of rapid, relatively low cost NGS technologies has allowed for a genetic diagnosis to be made in many more patients with PMD. Accurate genetic diagnosis allows physicians and affected families to better understand the condition and for the provision of appropriate genetic counseling. For some disorders where the natural history is better known, clinicians and families can more accurately predict the disease course and provide appropriate clinical management and preventative care.[33]

However, genetic testing in mitochondrial disease remains limited by aspects of tissue specificity of mutations in mtDNA, heteroplasmy, lack of understanding of the entire genome, VUS findings and an ever-growing list of nuclear disease genes. In the absence of functional testing, pathogenicity can only be assigned to genetic variants that have previously been observed to cause the same or highly similar phenotype in an unrelated family.[34]

**Testing mtDNA and tissue specificity**

MitDNA can now be accurately sequenced in its entirety for a relatively low cost. However, mtDNA heteroplasmy, with a varied distribution of point mutations or deletions in various post-mitotic tissues (e.g. muscle or brain), may lead to difficulties with diagnosis when assessing rapidly dividing tissues such as blood, where levels of mutated mtDNA may be extremely low. NGS has improved sensitivity so that it is now possible to detect levels of heteroplasmy of less than 5% in blood DNA. However, testing in blood cannot accurately determine mtDNA copy number or mtDNA deletions in a majority of cases.

In patients with suspected mitochondrial disease, the finding of low level heteroplasmy of a pathogenic mtDNA mutation does little to assist the clinician in determining if the mutation is
clinically relevant and if so, how the prognosis is affected. Low level heteroplasmy in blood does not exclude a pathogenic level of heteroplasmy in another tissue, especially if the patient’s symptoms are primarily muscle or brain related. In disorders that have been well characterized with clear heteroplasmy:phenotype relationships (e.g. MERRF m.8344G>A, MELAS m.3243A>G, NARP m.8993T>C/G) the finding of low level heteroplasmy (< 5 %) in blood is not always likely to be associated with neurological disease; however, assessment in other tissues is still recommended if the phenotype is compatible.

Incidental findings of mtDNA mutations at low level heteroplasmy are not uncommon, especially since ~ 1/200 asymptomatic people may carry a low level heteroplastic pathogenic mtDNA variant in blood.[35–37] Such variants are now even detected in patients tested by WES in whom mitochondrial disease may not have been strongly on the differential diagnosis list. It is quite easy to mistakenly attribute clinical relevance to low-level heteroplastic mtDNA mutations due to a clinician’s anchoring and confirmation bias even though it may not be the actual cause of a given patient’s constellation of medical problems.

Assessing mtDNA in other tissues such as muscle, liver or urinary epithelial cells may help when pathogenic mutations are not detected in blood or only low levels of a pathogenic mutation are found. MtDNA point mutation heteroplasmy analysis in urine provides another non-invasive, reliable and relatively inexpensive methodology that has been validated against skeletal muscle heteroplasmy, although testing is not available on a clinical basis in all regions.[38] Some mtDNA point mutations and large-scale or multiple deletions may only be detected in muscle or liver in some patients. Long-range PCR is the preferred method for detecting deletions as Southern blot analysis lacks sufficient sensitivity to detect low levels of heteroplastic deletions. Southern blot analysis remains useful for clarifying the type of rearrangement in patients with duplicated or deleted mtDNA.[39] Interpretation is complicated, as normal aging may lead to a low level of multiple mtDNA deletions in tissues including muscle, and accumulation of mtDNA deletions may be accelerated in other muscle disorders, particularly sporadic inclusion body myositis.
MtDNA copy number analysis for mtDNA depletion is also not yet routinely measurable by NGS or accurately quantifiable or always represented in blood. Such testing may become viable and cost effective via whole genome sequencing (WGS) or other NGS approaches in the near future. Currently, the most widely used approach if mtDNA depletion is suspected is to perform a quantitative real-time PCR assay, preferably in an affected tissue, although unaffected tissue (e.g. skeletal muscle in POLG-related Alpers-Huttenlocher syndrome) may still demonstrate a significant, albeit clinically silent, mtDNA depletion. Interpretation of mtDNA copy number data is critically dependent on appropriate age and tissue matched normal control ranges,[40] which can be difficult to obtain, thereby limiting applicability. Results may be equivocal even when normal control ranges are available. To complicate matters, mtDNA depletion has been identified in non-mitochondrial diseases including desminopathies, Parkinson disease, age-related changes in paraspinal muscles and as a consequence of antiretroviral therapy.[41–45]

**Heteroplasmic variants**

As mtDNA has a higher mutation rate than the nuclear genome, many individuals have rare or private mtDNA polymorphisms. Determining the pathogenicity of these polymorphisms remains challenging. Interpreting the genetic results in the light of clinical and laboratory findings and the family history may be helpful, but still may not provide a conclusive answer. MtDNA haplotyping may assist in establishing pathogenicity,[46] and the same mutation arising independently several times and co-segregating with clinical features may support a causal role.[47]

Even when pathogenicity is suspected, phenotypic variability remains pronounced. This is the case for many of the less common or novel pathogenic mutations in the mt-tRNA genes. Distinguishing novel pathogenic mutations from benign polymorphisms remains difficult. Research based testing to interrogate the pathogenicity of heteroplasmic mutations – via single fibre and/or trans mitochondrial cybrid studies – remains costly and labour intensive,[48] and is not possible for most patients.
Testing nuclear genes

Since the mitochondrial genome only encodes 13 mitochondrial proteins (and 24 tRNA and rRNA genes required for the intramitochondrial synthesis of these 13 proteins), nuclear genes encode almost the entire mitochondrial proteome. New genes impacting mitochondrial function and leading to human disease continue to be discovered. Many of the known disease-causing genes may be tested via gene panels and whole exome sequencing (WES) although the ability to detect a clearly pathogenic mutation in suspected PMD is imperfect, with a reported diagnostic yield ranging from 25-75%, dependent upon study design.[49–53]

WGS is beginning to be utilized beyond research-based testing but our current understanding remains limited. Many ongoing WGS analyses are restricted to assessing variants in the approximately 2% of the genome that represents the exome, owing to a very limited understanding of the consequences of sequence variants in other regions (promoters, deep intronic regions and other non-coding regions). Much of what the genome holds in regard to causing primary mitochondrial disease remains to be seen. This lack of a complete understanding of and the inability to meaningfully analyze variants in all the genomic elements involved in mitochondrial function greatly contributes to our inability to make genetic diagnoses in 100% of cases with suspected PMD.

Using current approaches, many suspected cases, both pediatric and adult, may still remain without a genetic diagnosis following WES or WGS.[54, 55] This figure will decrease as sequencing quality, bioinformatic analysis, and our ability to interpret variants throughout the genome improves. In addition, supplementary approaches such as RNA sequencing of the transcriptome and proteomics and metabolomics approaches are proving helpful in increasing the genetic diagnosis rate.[5, 55]

Nuclear gene variants
It is now well known that when analysing large numbers of genes by WES or WGS, tens of thousands of coding sequence variants will be identified in any given individual. Even after bioinformatic filtering of common benign polymorphisms, hundreds of putative significant variants remain. Interpreting these variants constitutes a huge challenge. In practice, one or more VUS is routinely identified. A multi-disciplinary team approach is necessary for optimal interpretation, bringing together clinical, biochemical, histological and genetic expertise. In the case of known mitochondrial disease genes, concordance with clinical and biochemical features can be complicated by weak genotype-phenotype correlation and the continuing widening of phenotype associated with a particular gene as more cases are identified. Further studies, including RNA sequencing or protein functional studies, may be necessary although these follow-up studies are often only available in a research setting.

For nuclear VUS, variant prioritisation following bioinformatic analysis[56–58] and database interrogation (e.g. 1000 Genomes,[55] ClinVar,[59] ExAC/gnomAD,[60] Medical Genome Reference Bank, MITOMAP,[61] MSeqDR,[62]), as well as classification using the American College of Medical Genetics (ACMG) criteria,[34] a search of known attributes of the affected gene and its transcriptional/translational products can inform an approach toward confirmation of pathogenicity.

The simplest approach for ascribing conditional pathogenicity is investigating segregation of a variant with disease in family members. This may be difficult when considering multisystemic mitochondrial diseases that can display high levels of phenotypic heterogeneity for the same gene or variant.[63] If familial segregation information is inconclusive or cannot be obtained, investigating larger cohorts of phenotypically similar patients for the same genotype may provide support for pathogenicity. As mentioned above, this may be difficult in the absence of a consistent genotype-phenotype correlation and additionally in the setting of a rare disease. In any case, segregation data must be accompanied by empirical evidence of a functional defect, requiring a synthesis of clinical tests and laboratory experiments to establish a pathological basis for the VUS. This may require a research laboratory with specialist interests in the gene or
disease in question and can be aided by the availability of patient-derived tissue samples or cell lines for investigations.

Validation of VUS pathogenicity is determined by the nature of the variant in question (missense, nonsense, splicing, indel, copy number variation, structural variant, etc.), the affected gene and its associated function and the biological/pathological relevance. Experimental evidence supporting pathogenicity (in addition to clinical presentation, phenotype/genotype correlation and theoretical evidence) could include imaging studies, biomarker measurements, or functional approaches in patient-derived tissue and cell lines or model organisms.

Functional biochemical testing in muscle or other tissues may help better ascertain the relevance of selected VUS and remains a necessary tool in some patients. Interpreting VUS remains an ongoing challenge although there are guidelines on how to better categorize these.[34] These are important considerations for accurate diagnosis and counselling of patients with PMD disorders, particularly at a time when reproductive choice has been expanded to include preimplantation genetic diagnosis and more recently mitochondrial donation.

mtDNA VUS

Novel mtDNA variants pose unique challenges for clinical correlation and interpretation given the challenges of performing functional validation studies, broad heterogeneity of PMD clinical phenotypes, and unknown threshold effects necessary for a given variant to manifest disease in particular organs. However, additional information at both bioinformatic and clinical levels can be readily attained to further understand the potential functional impact of a given mtDNA variant.

Several readily available bioinformatics tools now exist that can be used to efficiently gather information about novel mtDNA variants. For example, mvTool,[64] hosted on the
Mitochondrial Disease Sequence Data Resource (MSeqDR[62]), provides population level frequency data for mtDNA variants, a compilation of in silico variant pathogenicity predictor tools, and a collection of expert curated pathogenicity data from multiple sources including MITOMAP[61] and HmtDB.[65]

Guidelines and recommendations for mtDNA variants curation have also been developed by an expert panel to aid clinicians and molecular geneticists in proper interpretation. (Standards and guidelines for mitochondrial DNA variant interpretation. [Elizabeth M. McCormick et al. Human Mutation 2018 (accepted; under revision)])

Valuable information may also be gained from pursuing diagnostic testing of the mtDNA variant in question in multiple tissues from both the proband and family members, although this is not always possible due to family preferences and insurance restrictions. A higher level of heteroplasmy in more clinically symptomatic tissues provides strong supporting evidence for the likely pathogenicity of a given mtDNA variant.

Traditionally, the gold-standard definitive study to assess pathogenicity of a heteroplasmic mtDNA mutation was to generate a transmitochondrial cell line, by fusion of an enucleated patient cell with a rho zero cell lacking mtDNA, to determine whether a biochemical defect is transferred with the patient mtDNA.[66]
REFERENCES


17 Lane M, Boczonadi V, Bachtari S, Gomez-Duran A, Langer T, Griffiths A, Kleinle S, Dineiger


26 Hui J, Kirby DM, Thorburn DR, Boneh A. Decreased activities of mitochondrial respiratory


doi:10.1038/gim.2017.107


Case 1 Basal ganglia disease

Two sisters from a consanguineous family had a severe neurodegenerative disorder, characterized by infantile onset of profound intellectual disability, failure to thrive associated with severe feeding difficulties, seizures and dystonia. Pertinent investigations in the older proband included normal urine amino and organic acids, plasma acylcarnitines and blood lactate. CSF lactate was also normal. Nerve conduction studies were suggestive of an axonal neuropathy. Brain magnetic resonance imaging (MRI) at 13 months was notable for bilateral basal ganglia hyperintensities and cerebral atrophy. Muscle histology was nonspecifically abnormal. Muscle complex IV activity was 48% of the control mean relative to citrate synthase, and in liver was 32% of normal relative to citrate synthase. She died at 26 months of age. Her younger sister exhibited a very similar onset and course, but has survived, currently aged 13 years, albeit with profound intellectual disability, upper airway abnormalities and poor growth requiring gastrostomy feeding. A brain MRI at seven months of age also showed bilateral symmetrical basal ganglia hyperintensities. She did not have any biopsies but her serum FGF21 was elevated at 1400 pg/ml (normal < 300). Together, these features were highly suggestive of an underlying mitochondrial electron transport chain (ETC) disorder primarily affecting complex IV. However whole genome sequencing revealed a homozygous variant in the SLC39A8 gene (Riley et al 2017), which was recently identified to cause a manganese transporter disorder also impacting glycosylation. (Boycott et al 2015). Manganese is a cofactor for manganese superoxide dismutase, without which there is an increase in oxidative stress and decrease in ROS scavenging. (Riley et al 2017 PMID: 27995398) Subsequent analysis of serum transferrin isoforms revealed a profile consistent with the expected type II congenital disorder of glycosylation pattern.

Case 2 Ophthalmoplegia and myopathy

Two brothers (68 and 80 years old) from a non-consanguineous family were evaluated for progressive ptosis, ophthalmoplegia, dysphagia and mild limb-girdle muscle weakness since their 50s. Pedigree analysis was suggestive of maternally inherited autosomal dominant disease, with no clinical anticipation. Blood tests, including creatine kinase (CK) and lactate,
were normal in both brothers. Electromyography (EMG) studies revealed myopathic changes, and a muscle biopsy performed in the older brother (at the age of 70 years) showed rare ragged red and cytochrome c oxidase (COX) negative fibers (5% for both). Long-range PCR analysis revealed multiple mtDNA deletions in muscle. However, next generation sequencing (NGS) analysis of genes involved in mtDNA maintenance was negative. Further analysis of the PABPN1 gene revealed expansion of 13 GCN trinucleotide repeat in the first exon, thus shifting the diagnosis to oculopharyngeal muscular dystrophy (OPMD). OPMD and myotonic dystrophy are two genetic illnesses in addition to many mitochondrial disorders where ptosis, incomplete ophthalmoplegia, dysphagia and myopathy are common features. As NGS technology improves, the nucleotide repeat disorders will be more easily identified.

Case 3 Lactic acidosis and atrophy of the putamen
A one-year-old boy was evaluated for hypotonia and motor regression. He was normal at birth but late in the first year of life he was found to have lost motor tone. He had undergone extensive biochemical evaluation prior to his initial assessment at the specialist center. Physical examination was normal other than extreme hypotonia. He had no speech but was attentive and smiled socially. On direct enquiry, mother had not observed any crystals in his urine. MRI brain showed mild parenchymal atrophy and volume loss bilaterally in the putamen and thalamus. Blood lactic acid was elevated at 6 mmol/L. A muscle biopsy was performed, showing normal histology but the enzymatic activity of complex I (I+III assay) was 25% of the mean control. He was treated with coenzyme Q10, levocarnitine and a B vitamin complex for presumed complex I disease. His examination over the next few years showed him to be an alert and visually interactive child who did not develop language function and had continued severe hypotonia with progressive but mild dystonia. At the age of 5 years, he arrived for a routine examination wearing gloves, to protect his fingers from a recent onset of biting behavior (self-mutilation). The uric acid level was elevated and hypoxanthine phosphoribosyl-transferase enzyme activity was less than 10% of control values. Genetic testing was not performed but the patient’s clinical course followed that typical of Lesch-Nyhan disease. The history of progressive hypotonia with evolving dystonia, language delay, lactic acidosis, deep
gray matter loss and generalized brain parenchymal volume loss, together with the low complex I ETC activity seemed to fit together with a primary mitochondrial disorder. With our current knowledge regarding altered concentration of nucleotide pools affecting mtDNA replication, it seems likely that the abnormal purine concentrations could result in mtDNA depletion, although this was not confirmed in this patient.

**Case 4 Cognitive decline with ataxia and dystonia**

The patient, a 20-year-old male, was born at term (weight 3.01kg) to unrelated parents following an uncomplicated pregnancy and normal delivery. He displayed mild early gross motor development delay (crawled at 14 months, walked at 18 months) but language development was normal.

He first presented to the paediatric service at the age of 6 years with an episode suggestive of a nocturnal tonic-clonic seizure. A history of ‘blank spells’ from age 6 months was noted by his mother. Neurological examination was normal but an electroencephalogram (EEG) demonstrated bilateral independent foci in both temporal regions and he was commenced on carbamazepine. His school performance was above the average expected for his age group. He remained under follow up and these events were eventually deemed non-epileptic, and carbamazepine was weaned.

Between the ages of 10 and 12 years, there was emerging concern that the quality of his school-work had declined. However, neuropsychological assessment at age 12 years demonstrated that he was still working within the normal expected range, albeit at the lower end (10th centile for verbal comprehension; 5th centile perceptual reasoning; 55th centile for working memory). However, by the age of 14 years there was a clear and objective deterioration. He had also started tripping frequently; was struggling to button, zip or tie laces; his speech had declined; and there was prominent daytime somnolence.
On clinical examination there were no dysmorphic or neuro-cutaneous signs. Cranial nerve examination, including eye movements, was normal. Tone was normal, but reflexes were brisk throughout, plantar responses were down-going. No sensory abnormalities were evident. He had a clumsy gait, with an inability to tandem walk, mild dystonic posturing and subtle choreiform movements of the upper limbs. Cerebellar dysarthria, and finger-nose, heel-shin and truncal ataxia were noted. Cognitive assessment revealed emotional lability and poverty of mentation.

MRI brain demonstrated bilateral symmetrical increased signal in the white matter adjacent to the posterior horns of the lateral ventricles. Routine laboratory tests were normal including ferritin, transferrin isoforms, thyroid function, cholesterol, triglycerides, lipids, copper, ceruloplasmin, lysosomal enzymes, very long chain fatty acids, vitamin E, biotinidase, intermediate metabolites, lactate, pyruvate, ammonia, urate, amino acids, urinary organic acids and mucopolysaccharide screen. Genetic tests for DRPLA, Friedreich ataxia, spinocerebellar ataxias (SCA1, 2, 3, 6, 7 and 17) and Huntington disease were negative. No concerning features were identified on slit lamp examination. Visual evoked potentials (VEP) and electroretinogram (ERG) were normal.

At age 15 years, the patient was referred to a regional neuro-genetic clinic where a mitochondrial aetiology was explored, given the clinical features and imaging findings. Thiamine was commenced but without clinical improvement. Muscle biopsy was undertaken for ETC enzyme analysis which identified a complex I deficiency (0.051 U/UCS; normal 0.104+0.036) with low complex I:II ratio (0.05; normal 0.52-0.95). Muscle histochemistry was normal. Array CGH was normal and further genetic testing for mutations in POLG, MTATP6, MTATP8 and MTTK (associated with MERRF phenotypes) were all negative.

At clinical review at 18 years of age, symptoms had progressed and the patient was having increasing problems with falls, speech, and cognitive decline. There was a history suggestive of
mild cataplexy with heightened emotion and giggling triggering brief head drop. Examination revealed a mixed dystonic-ataxic gait, myoclonic jerks and a supranuclear gaze palsy. Given the clinical features, a sample for plasma oxysterols was sent. Cholestan-3b, 5a, 6b-triol was found to be elevated at 55.4 ng/ml (normal range 8.1-37.7 ng/ml) and pathogenic compound heterozygous mutations were identified in NPC1 (c.3182T>C;p.lle1061Thr and c.3566A>G;p.Glu1189Gly) which confirmed the diagnosis of Niemann-Pick disease type C. The patient was referred for commencement of miglustat therapy.

Photograph and video of the patient at 18 years of age.

Case 5: mtDNA pathogenic mutation with low level heteroplasmy in blood
A 43-year-old Romanian woman presented with normal early development except for lifelong clumsiness and progressive multi-systemic disease since her 20s. Her disease was progressive and severe, including complex epilepsy since age 20 with generalized seizures and then myoclonic jerks with diffuse slowing and multi-focal periodic lateralizing epileptiform discharges on electroencephalogram, mild cortical atrophy on computed tomography (CT) at age 40 and more diffuse cortical atrophy on brain MRI at the time of her first stroke at age 42. She had recurrent acute "metabolic" strokes in the posterior parietal and medial occipital-
temporal cortex at age 42 with residual hemiplegia, hypertonia, walker or wheelchair
dependence, dysarthria, and permanent left peripheral vision loss. She developed cognitive
decline from her mid-30s including psychosis, delusions and functioning estimated at a second-
grade level. She also had migraines. Additional systemic manifestations include vertical and
horizontal ophthalmoplegia, bilateral progressive sensorineural hearing loss onset at 30, left
ventricular hypertrophy (LVH), a patent foramen ovale, nausea and vomiting with stress,
irritable bowel syndrome, gastroesophageal reflux disease, bilateral renal cysts, and early
morning carbohydrate craving and cloudy cognition that improved with eating. Testing showed
elevated lactate intermittently in blood (4 mM; normal < 2.2) and CSF (4.2 mM; normal < 2.2),
and mildly elevated glutaryl dicarboxylic acid on plasma acylcarnitine analysis.

Her family history was significant in that her mother had type II diabetes diagnosed at age 56
and an episode of paralysis at age 56, poor balance with apparent peripheral neuropathy,
cortical atrophy, sudden complete hair loss in her 30s with thinner hair regrowth over time, and
sensorineural hearing loss onset in her 70s. Her maternal grandmother had extreme fatigue.

Muscle biopsy at age 42 showed mild myofiber size variation, hypertrophic and atrophic fibers,
one necrotic fiber, rare degenerating but no regenerating fibers, an unquantified number of
ragged red fibers, targetoid and small dark fibers on NADH-TR staining, significant type II > I
fiber atrophy, increased SDH positive fibers, and 5-10% COX negative fibers. No biochemical or
genetic testing was performed on muscle.

A low level (8%) of the mitochondrial DNA (mtDNA) mutation m.3243A>G that causes
Mitochondrial Encephalopathy Lactic Acidosis and Stroke-like episodes (MELAS) syndrome was
detected in her blood. This same variant was subsequently found by highly sensitive ARMS
qPCR analysis to be at similarly low levels (4% in blood, 7% in urine) in her mother. Urine
heteroplasmy testing in the proband revealed 60% m.3243A>G mutant heteroplasmy load,
which was clinically significant and confirmed the diagnosis of MELAS spectrum disorder.
Typical heteroplasmy levels in symptomatic patients are in the 25-90% range. However, a wide range of multi-systemic diseases that poorly fit into a pre-defined clinical syndrome can often be seen.[1, 2] It is well-known that the m.3243A>G mutation load is selected against and decreases over time in blood at the same time it may persist or increase in other tissues such as urine, which reflects shed renal cells.[3–6] A software tool to model the expected tissue heteroplasmy levels in individuals with the m.3243A>G mutation in blood is available at the Newcastle Wellcome Trust website (www.newcastle-mitochondria.com/).

Case 6: mtDNA VUS

A 19-year-old Caucasian man presented with progressive multi-system involvement. Several features were attributed to a congenital open neural tube defect (L5/S1 myelomeningocele) including complete paraplegia of lower extremities, lack of bladder and bowel control, and Chiari malformation requiring shunt placement. However, additional multisystem involvement unexplained by the myelomeningocele was ultimately found to be related to a novel pathogenic mtDNA variant (Schrier et al., 2012). As previously reported, these manifestations included developmental delay and intellectual disability, hypotonia, bilateral severe mixed hearing loss, moderate to severe LVH, Wolff-Parkinson-White syndrome, severe retinal dystrophy, bilateral dense nuclear cataracts requiring extraction, hypopituitarism, growth deficiency, type II diabetes mellitus, hypogonadism, truncal obesity, and osteopenia. Family history was non-contributory. The proband’s mother was healthy until her death in a motor vehicle accident in her early 30s.

Metabolic screening studies showed persistently elevated blood alanine (492 nmol/mL and 708.9 nmol/mL; normal 88-440) and intermittently elevated blood lactate (1.54 mM and 2.8 mM; normal <2). Skeletal muscle biopsy findings in biceps (proband recently received botox injections to both quadriceps) were consistent with a mitochondrial myopathy (unquantified number of ragged red fibers and absence of COX staining in scattered fibers; electron microscopy revealing irregular branched mitochondria, focal mitochondrial collections, and
mitochondrial lipid deposits). ETC enzyme activities were within normal limits and citrate synthase was increased (159% of mean).

Clinical molecular testing available at the time (2007-2008) was unrevealing, including karyotype, microarray, BBS1 and BBS2 gene sequencing, mtDNA common point mutation and deletion analysis in blood, and mtDNA deletion and duplication analysis in muscle. A homoplasmic novel variant, m.12264C>T in MTTS2 encoding mitochondrial tRNA-serine 2, was identified in muscle by mtDNA whole genome sequencing. Research-based mtDNA heteroplasmic quantitation was performed in blood, buccal, muscle, and extracted cataract samples from the proband and blood and buccal samples from the proband’s father and maternal grandmother. The variant was found to be homoplasmic in the proband’s muscle, extracted cataract, and buccal sample, and heteroplasmic in blood (34%). His father did not have the mtDNA variant. His maternal grandmother was found to have the m.12264C>T variant at 1% heteroplasmy level in blood and 18% heteroplasmy level in her buccal sample. His mother was deceased and a sample was not available for testing.

Case 7: OPA1 VUS

A 67-year-old Caucasian male presented with fatigue, disturbed sleep, muscle pain, weakness and numbness. Clinical examination revealed lower limb distal muscle weakness and wasting, peripheral neuropathy, mild sensorineural hearing loss, mild bilateral ptosis, dyspnea, dysphagia and dysarthria with bulbar and respiratory muscle weakness, as well as dyslipidaemia and elevated transaminase levels. A muscle biopsy showed histological changes consistent with mitochondrial myopathy, including increased subsarcolemmal staining with Gomori trichrome and COX-negative fibres (quantity not known). The family history was unremarkable and did not indicate a likely mode of inheritance.

Serum levels of FGF21 were elevated at 798, 691 and 812 pg/ml (control range < 350 pg/ml on longitudinal sampling, potentially supporting a muscle-manifesting mitochondrial disease. Long-range PCR of the mitochondrial genome showed a 16.5kb amplicon with no evidence of large-
scale deletions. Deep sequencing of the entire mtDNA amplified by long-range PCR revealed no significant variants. Bioinformatic analysis of known mitochondrial and neuromuscular disease genes from whole genome sequencing (WGS) of blood genomic DNA revealed a heterozygous, in-frame, 18 nucleotide deletion in \textit{OPA1} (NM_015560.2(\textit{OPA1}):c.113_130del18 (p.Arg38_Ser43del)) that was confirmed by Sanger sequencing on a separate blood sample. The deletion locates to exon 2 of \textit{OPA1} and potentially interferes with the mitochondrial targeting sequence of the protein. There are reports of at least 9 other individuals with the same deletion in ClinVar, however it is classified as a VUS owing to conflicting descriptions of associated pathogenicity and phenotype (https://www.ncbi.nlm.nih.gov/clinvar/variation/214916/#supporting-observations).

\textit{OPA1} encodes a mitochondrial inner-membrane protein with dynamin-related GTPase activity that is required for maintenance of cristae structure (in doing so regulating apoptosis), the mitochondrial reticulum (by mediating mitochondrial fusion) and the mitochondrial genome. Autosomal dominant pathogenic variants in \textit{OPA1} (OMIM 605290) are associated with Optic Atrophy 1 (Phenotype MIM 165500), an optic neuropathy affecting retinal ganglion cells and leading to blindness, and also dominant optic atrophy plus (Phenotype MIM 125250), which has systemic manifestations (e.g. hearing loss, myopathy and neuropathy) in addition to optic atrophy. As the patient described here had no evidence of optic atrophy he was not initially considered for \textit{OPA1} genetic testing. However, his symptoms do fit with the extraocular manifestations of dominant optic atrophy plus.

\textit{Case 8: Spasticity and mitochondrial dysfunction}

The now 43-year old patient presented in the early 1990s, during late adolescence, with new onset academic difficulties in high school. Over the next few years she had difficulty with ambulation. Her examination when first evaluated about 8 years after her symptoms began revealed mild cognitive dysfunction, dysarthria, spasticity and neuropathy. Her initial brain MRI was normal but her biochemical evaluation revealed consistently elevated pipecolic acid levels (range of 2.7-4.7 \text{uM} (control 0.7-2.5). Detailed evaluation for known peroxisomal disorders
was performed with the advice and assistance of experts in this group of disorders, and was not revealing. A liver biopsy was performed in 1999 to confirm what was believed to be a peroxisomal disorder. The EM of the liver demonstrated normal peroxisomal appearances but massive and abnormally shaped mitochondria with paracrystalline inclusions. A subsequent muscle biopsy showed ragged blue fibers (amount not specified) and a biochemical defect in ETC Complex I, I+III and III (amounts not specified). The patient did not have consistent abnormalities in lactic acid, blood amino acids or urine organic acids, but because of the histopathology and biochemical findings, the working diagnosis was believed to be a mitochondrial disease. Over the next 13 years the patient underwent genetic testing in a sequential fashion that included screening for common mtDNA mutations, Southern blot for mtDNA deletions, whole genome mtDNA sequencing, and sequencing of numerous individual nuclear genes. This testing did not reveal any mutations that would explain her phenotype. Her clinical symptoms worsened and the patient currently has difficulty speaking in sentences because of both cognitive limitations and dysarthria. She spends most of her day in a wheelchair, with a limited ability to ambulate. In addition to the spasticity and neuropathy her clinical findings now include retinal degeneration, scoliosis, pes cavus, myopathy, ataxia and parkinsonism (stooped posture, masked facies and bradykinesia). The brain MRI shows moderate generalized volume loss. In 2012 sequence analysis of a large panel of nuclear-encoded mitochondrial genes (> 250 genes) was normal. In late 2013 WES was reported to show a number of possible candidate mutations. These included compound heterozygous mutations in TIMM44. Both mutations were predicted in silico to be pathogenic, but this mitochondrial gene had not been reported to be associated with any clinical disease. In addition, a nonsense mutation was found in SPG11, which was also present in the patient’s father, but not mother. Because only one mutation was identified in SPG11 (a gene whose defects typically cause autosomal recessive disease) and a phenotype that partially matched the phenotype (no cerebellar atrophy or thinning of the corpus callosum was identified), both SPG11 and TIMM44 remained candidate genes. Further genetic evaluation was delayed because of costs and the need for insurance approval to pay for the testing but in 2015 del/dup analysis of SPG11 was performed and revealed the previously identified c.1744G>T
(p.Glu5882*) mutation, also identified in the father, as well as partial deletion of the gene including exons 17 and 18, which was found in her mother a year later. The gene product of **SPG11** controls the assembly of the ribosomes in the mitochondria and is associated with the clinical illness autosomal recessive spastic paraplegia type 11 (OMIM 604360), which is a good fit for this patient’s illness. The liver pathology and biochemistry reported in this case suggest this gene, and disease, could be considered as a primary mitochondrial disorder, although it is not known if the mutations in **TIMM44** play a role in the patient’s phenotype. Future technological advances may help to address this question as the patient and her family wish to pursue this question. Of note, her GDF15 is elevated at 955 pg/mL (control range < 750). This case illustrates a two-decade journey through technological advancements that eventually led to the diagnosis, possibly led astray by unexpected laboratory findings. Had the initial evaluation not identified the consistent elevation in pipecolic acid, the liver biopsy would not have been performed and the subsequent evaluation would likely not have led down a mitochondrial pathway. An explanation for the elevation in pipecolic acid remains unclear. If the initial clinical suspicion led towards a spastic paraparesis evaluation, the results of genetic testing would have likely stumbled across the same technological issues, specifically early massively parallel sequencing failed to identify many deletions, duplications or insertions.
REFERENCES


